Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553602 · ClinicalTrials.gov registry record · Phase 1
HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer
A Phase 1 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03553602 is a Phase 1 study that was terminated before completion, run by Loyola University. The registered enrollment target is 3 participants.
The verdict
NCT03553602, a Phase 1 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short term androgen deprivation therapy (STAD), as treatment for prostate cancer that has come back in the prostate and pelvic lymph nodes after prior radiotherapy. The study will examine the side effects of the treatment as well as the ability of the treatment to get rid of the cancer. This involves the placement of a radioactive material in the affected area of the prostate temporarily, and then is subsequently removed using a minimally invasive technique. Participants will also receive external radiation for 5 weeks targeting the pelvis and giving a higher dose each day to the suspicious lymph nodes on PET scan. Radiation therapy will start approximately 2 months after the start of the Androgen Deprivation Therapy (hormone therapy). The hormone therapy consists of two medications, an oral medication taken daily 2 months before starting radiation therapy until the last of the radiation therapy and an injection of a medication which is given 2 months prior to the start of radiation. Patient are then followed at specific time intervals to evaluate the treatment side effects and cancer control
Interventions
- DRUG HDR Brachytherapy + EBRT + STAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2024-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03553602
The ClinicalTrials.gov registry entry for NCT03553602 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HDR Brachytherapy + EBRT + STAD is the first listed.
NCT03553602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03553602 about?
NCT03553602 is a clinical study titled "HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer". The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short term androgen deprivation therapy (STAD), as treatment for prostate ca...
What is the current status of trial NCT03553602?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-12-20. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT03553602?
The interventions under investigation include: HDR Brachytherapy + EBRT + STAD (DRUG).
Who is sponsoring clinical trial NCT03553602?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.